For Marketing Authorisation Holders (MAHs), pharmacovigilance compliance is a fundamental regulatory obligation. At the core of this obligation sits the Qualified Person for Pharmacovigilance (QPPV) a legally accountable role under both UK and EU pharmacovigilance legislation. Regardless of how pharmacovigilance (PV) activities are structured or outsourced, the responsibility for patient safety and regulatory compliance remains firmly with the MAH.
As outsourced and hybrid PV models become increasingly common, regulators are placing greater emphasis on what constitutes real QPPV oversight. Simply appointing a QPPV or outsourcing PV activities to a service provider is no longer sufficient. MAHs must demonstrate that their QPPV exercises active, continuous, and effective control over the pharmacovigilance system.
The Regulatory Role
Under UK pharmacovigilance requirements and EU Good Pharmacovigilance Practice (GVP), every Marketing Authorisation Holder (MAH), including virtual, start-up, and multinational organisations, must appoint a Qualified Person for Pharmacovigilance (QPPV). Regulators such as the MHRA and EMA expect the QPPV to have sufficient authority, independence, and unrestricted access to safety data.
The QPPV is responsible for the oversight and effective functioning of the pharmacovigilance system, whether activities are performed in-house or outsourced. Core regulatory responsibilities and services include:
- Oversight of global and local pharmacovigilance systems, including third-party providers
- Creation, maintenance, and control of the Pharmacovigilance System Master File (PSMF)
- Review and approval of safety agreements, SOPs, and PV governance documentation
- Involvement in signal detection, risk management, and safety decision-making
- Participation in safety committees and governance forums
- Availability for regulatory inspections, urgent safety issues, and authority interactions
- Support for inspection readiness, with clear escalation pathways and defined responsibilities
Outsourced Pharmacovigilance Models: Opportunities and Risks
Outsourcing pharmacovigilance activities has become a strategic choice for many MAHs seeking flexibility, scalability, and access to specialist expertise. Commonly outsourced activities include case processing, literature screening, aggregate reporting, and signal management.
While outsourced PV models can be effective, they also introduce regulatory and operational risks if not governed correctly.
Commonly outsourced pharmacovigilance activities include:
- Individual Case Safety Report (ICSR) processing
- Medical literature monitoring
- Signal detection and evaluation
- PSUR, PBRER, and DSUR preparation
Without strong QPPV oversight, MAHs risk losing visibility of safety data, weakening quality controls, and failing to meet inspection expectations.
What Defines “Real Oversight” in Outsourced PV Models
Regulators are increasingly focused on whether QPPVs demonstrate active oversight, rather than acting as a nominal or administrative function. Real oversight means the QPPV understands the system in practice, not just on paper.
Effective QPPV oversight is characterised by:
- Clear governance and decision-making authority
- Regular review of vendor performance and compliance metrics
- Ongoing involvement in safety issue management and escalation
- Continuous awareness of product safety profiles and emerging risks
A QPPV must be able to explain how safety decisions are made, how vendors are controlled, and how compliance risks are identified and mitigated.
Vendor Oversight: A Critical QPPV Responsibility
In outsourced pharmacovigilance models, third-party vendors often perform the majority of operational activities. Regulators expect MAHs and QPPVs to retain control through structured and ongoing vendor oversight.
Effective vendor oversight includes:
- Defined Service Level Agreements (SLAs) and KPIs
- Routine compliance monitoring and quality reviews
- Pharmacovigilance audits and follow-up of CAPAs
- Formal escalation of issues and risk management
The QPPV must be able to demonstrate how vendor performance is assessed and how deficiencies are addressed in a timely and compliant manner.
Inspection Readiness and Regulatory Scrutiny
During MHRA and EMA pharmacovigilance inspections, QPPVs are routinely interviewed to assess their knowledge, authority, and oversight of the PV system. Inspectors evaluate both documentation and practical system control.
Inspection focus areas often include:
- QPPV awareness of key safety concerns and signals
- Oversight of outsourced pharmacovigilance providers
- Timeliness and quality of case processing
- Effectiveness of the quality management system
A robust QPPV service ensures the MAH remains inspection-ready at all times, not just during announced inspections.
Common Pitfalls in Outsourced QPPV Arrangements
Despite good intentions, many MAHs fall into common traps when outsourcing QPPV services or PV activities.
Frequent challenges include:
- QPPVs lacking sufficient authority or system access
- Over-reliance on vendors without independent oversight
- Inadequate documentation of governance activities
- Limited QPPV involvement in safety decision-making
Addressing these risks requires a proactive, partnership-based approach to QPPV services.
Selecting the Right QPPV Service Provider
Choosing the right QPPV service provider is a strategic decision that directly impacts regulatory compliance and patient safety. Experience, credibility, and practical oversight capability are essential.
MAHs should seek QPPV providers who offer:
- UK and EU pharmacovigilance expertise
- Proven MHRA and EMA inspection experience
- Clear governance and communication structures
- Scalable support aligned to business growth
A strong QPPV service functions as an extension of the MAH’s leadership team.
How Quality and Vigilance Ltd Supports MAHs
Quality and Vigilance Ltd provides expert QPPV services for MAHs, delivering genuine oversight within outsourced pharmacovigilance models. Their approach focuses on regulatory confidence, inspection readiness, and practical control of PV systems.
Quality and Vigilance Ltd supports MAHs through:
- Experienced UK and EU QPPVs
- Continuous QPPV availability and compliance assurance
- Oversight of outsourced pharmacovigilance vendors
- PSMF management and system governance
- Support during MHRA and EMA inspections
By combining regulatory expertise with hands-on oversight, Quality and Vigilance Ltd helps MAHs ensure that outsourcing strengthens pharmacovigilance compliance rather than undermining it.